Full Fed. Circ. Told Teva Overreacting In Skinny Label IP Case

By Britain Eakin (December 7, 2021, 7:17 PM EST) -- Teva's warning that a second split panel decision reviving GlaxoSmithKline's $235 million jury win over its heart failure drug Coreg will have a "seismic" impact on the drug industry is overblown, GSK has told the full Federal Circuit.

In a brief filed Monday, GSK urged the full court to deny Teva Pharmaceuticals' October petition for en banc review of the panel's August rehearing decision. GSK said Teva's argument that the revised panel decision still dooms the so-called skinny label regime, which allows generic manufacturers to get regulatory approval for unpatented uses of branded drugs, is itself doomed because the panel properly applied the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!